Yijia Geohas
24 Feb 2015

Curriculum Vitae
February 24, 2015

Yijia Geohas, MS, MBA
Site Director & Clinical Research Coordinator

Evanston Premier Healthcare Research LLC
2500 Ridge Avenue, Suite 109
Evanston, IL 60201
Phone: (847) 869-1191
Fax: (847) 869-6975
Email: ygeohas@evanstonpremier.com

EDUCATION:

M.B.A. University of Chicago Graduate School of Business 2004
Concentration: Finance, Entrepreneurship, Strategic Management
M.S. University of Iowa 1997 Majors: Mathematics, Computer Science
B.S. Mount Mercy College 1995 Majors: Computer Science, Mathematics

Research project: Women in Mathematics, UC Berkeley, summer 1994

PROFESSIONAL EXPERIENCE:

2012-present Evanston Premier Healthcare Research LLC – Research Coordinator

07/98-03/05 UBS Investment Bank- Software Developer/Database Administrator

6/97-7/98 Cambridge Technology Partners – Developer/Consultant

1/95-9/95 Decisionmark Inc. - Intern, Software Engineer

CERTIFICATIONS:

2014-present	Novartis Epro Essentials
2014-present	Clinical Ink SureSource v5 Training for Coordinators
2014-present	eCRF Completion Guidelines v1.0 Ferring Pharmaceuticals
2014-present	medidata Uni. - Rave EDC Essentials for Clinical Research Coordinators
2014-present	AE Reporting (Males and Females) v1.0 Ferring Pharmaceuticals
2014-present	medidata Uni. Rave EDC Essentials for Clinical Research Coordinators
2013-present	GCP and Study Management v1.0 Ferring Pharmaceuticals
2013-present	Self-Injection Video and Guides
2013-present	Adverse Event Reporting Responsibilities and Procedures
2013-present	Inform GTM 5.5 for Site Users
2013-present	ClinTrakEDC Training-CRC
2013-present	Ethics and Compliance Overview v2.0
2013-present	Regulatory Requirements V1
2013-present	medidata Uni. Rave 5.6 EDC Essentials for Clinical Research Coordinators
2013-present	medidata Uni. Meaning of Electronic Signature and Security Requirements
2013-present	Protocol Overview, eCRF Completion Guidelines, AE Reporting, GCP and Study Management
2013-present	Oracle Clinical Remote Data Capture eCRF Training for Site Users V3.0
2013-present	Clinical Trial Portal – eTMF Training
2013-present	Clintrak SM/IVRS Version 12.3.16
2013-present	Almac Clinical Technologies Web IXR

2013-present	Bioclinica EDC
2013-present	Bracket IVRS/IWRS
2013-present	Medrio eCRF Data Entry Overview
2012-present	Adverse Event Definitions and Reporting in Clinical Studies
2012-present	Audits and Inspections
2012-present	Handling of Source Documents at Investigator Sites
2012-present	Investigator Responsibilities in Conducting/Supervising Studies
2012-present	Drug Inducted Liver Injury (DILI)
2012-present	eCRF Training for Site Users V3.0
2012-present	Biomedical Research, Basic Course
2012-present	CITI Good Clinical Practice Course, Basic Course
2012-present	CITI Health Information Privacy and Security (HIPS) for All Researchers, Basic Course
2012-present	Medidata Balance Logistics for Site Users
2012-present	Rave 5.6 EDC Essentials Clinical Research Coordinators
2012-present	Phase Forward Inform EDC version 4.6
2012-present	Transport of Dangerous Goods – Saf-T-Pak Inc.

CURRENT RESEARCH:

June 2012- A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of XXXXXX in High Cardiovascular Risk Patients with Hypercholesterolemia Not Adequately Controlled with Their Lipid Modifying Therapy

A Phase 2, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of XXXX in Patients with Type 2 Diabetes Mellitus

PDT-01-Safety and Efficacy of XXXX in Patients with Hyperlipidemias: A Pilot Study

Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of XXXXXXX in Subjects with Inadequate/Partial Response to Antidepressants during the Current Episode of Major Depressive Disorder

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial to Assess the Effects of XXXXXX on Women with Recent History of Urinary Tract Infections

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of XXXXXX in Patients with Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy

A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and tolerability of XXX once Weekly Suspension to XXXXX and Placebo in Subjects with Type 2 Diabetes Mellitus

A randomized, open-label, active-controlled, 3-arm parallel-group, 26-week study comparing the efficacy and safety of XXXXX to that of XXX XXX once daily and XXX XXX three times daily in patients with Type 2 diabetes insufficiently controlled with XXX XXX with or without metformin

An Efficacy and Safety Study of XXXX in Adults with Hypertriglyceridemia

A Double-blind, Randomized, Placebo-controlled, Phase 3 Trial in Patients with Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of XXXXX for 12 Weeks Followed by a 4-week Withdrawal Period

A Multicenter, Open-label, Safety and Tolerability Extension Trial of XXXXX Daily in the Treatment of Chronic Idiopathic Constipation

A Randomized, Double-Blind, (Test Products and Placebo), Chronic Dosing (24 Weeks), Placebo-Controlled, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of XXXX, XXXX, and XXXX in Subjects With Moderate to Very Severe COPD, Compared With Placebo and XXXX (XXXX, Open-Label) as an Active Control

A 28-Week, Multi-Center, Randomized, Double-Blind, Parallel-Group, Active-Controlled Safety Extension Study to Evaluate the Safety and Efficacy of XXXX, XXXX, and XXXX in Subjects With Moderate to Very Severe COPD, With XXXXX as an Active Control

A Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled, 24-Week Study to Evaluate the Efficacy and Safety of Daily Oral XXXXX Compared With XXXXXX When Used in Combination With Metformin in Subjects With Type 2 Diabetes

A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of XXXXX mg Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subject

A Double-Blind, Randomised, Placebo-Controlled Multi-Centre Field Study to Assess the Efficacy and Safety of XXXX Peptide Immunotherapy in Cat Allergic Subjects

A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12 Week Phas II Proof of Concept Study to Evaluate the Efficacy and Safety of XXXXXX Once Daily Versus Placebo in Statin Stable Subjects with Mixed Dyslipidemia

A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men with Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment with XXXX or XXXX

A 20-week, double-blind, randomized, placebo-controlled, parallel-group trial to assess the safety and efficacy of XXXX on body weight in obese subjects without diabetes

A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study To Assess The Efficacy, Safety And Tolerability Of XXXXX In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events

Phase 3 Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Evaluation Of The Efficacy, Safety, and Tolerability Of XXXXX, In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects

Phase 3 Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of XXXXX, In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk

A Multinational, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of XXXXXX twice daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients with Type 2 Diabetes Mellitus

A 26 week, randomized, active-controlled safety study of double-blind XXXXX XXXXX in free combination with an inhaled corticosteroid versus an inhaled corticosteroid in adolescent and adult patients with persistent asthma

A randomized, open-label, active-controlled, parallel-group, multicenter, long-term safety trial of treatment with nebulized XXXX in patients with COPD: Golden-5 (XXX for Obstructive Lung Disease via electronic nebulizer)

An Efficacy and Safety Study of Sustained-release XXXXXX in Subjects with Osteoarthritis

A phase II, 16-week, double-blind, placebo-controlled, parallel-group, randomized, multicentre trial to assess effect on glycaemic control of three doses of XXXXX in subjects with inadequately controlled type 2 diabetes receiving a stable dose of metformin

Open-Label Extension Study of EFC12492, R727-CL-1112, EFC12732, & LTX11717 Studies to Assess the Long-Term Safety and Efficacy of XXXXX in Patients with Heterozygous Familial Hypercholesterolemia

SKILLS AND SPECIALITIES:

Foreign Languages: Mandarin Chinese, Shanghai Dialect